A review of market access for cervical cancer treatments shows that under the pharmacy benefit, about 33% of the lives under commercial formularies are covered with utilization management restrictions. Around 65% of the lives under Medicare formularies are not covered for at least one of the drugs.
As Weight Loss Drugs’ Star Rises, Plan Sponsors, Researchers Worry About Costs
In recent months, the interest in prescription weight loss medications has grown exponentially as celebrities tout the drugs and clinical trial results show their safety and effectiveness. However, while tens of millions of people could benefit from the medications, health policy experts tell AIS Health that payers are taking a cautious approach and are concerned at the financial impact if the FDA approves more drugs for that indication, as is expected.
A recent survey from the International Foundation of Employee Benefit Plans found that 22.1% of employers last year offered prescription drug coverage for weight loss, including 21.3% of corporations, 22% of public employers and 27% of multiemployer plans. Of the 470 companies that responded to the survey, 25% said obesity is one of the top three health conditions that has the largest impact on overall health costs.
Commercial Insurance Restrictions Complicate Biosimilar Adoption
Since the FDA’s approval of the first biosimilar in 2015, the agency has approved almost 40 more agents. However, their adoption in the U.S. market has been slow. A recent study, published in the journal BioDrugs, found that biosimilars were covered more restrictively than their reference biologics in 19.4% of coverage decisions made by select commercial health plans.
The study examined 1,181 coverage decisions made by 17 commercial health plans as of August 2021 from the Tufts Medical Center Specialty Drug Evidence and Coverage database, which included 19 commercially available biosimilars for seven biologic reference products used in treating 28 conditions.
MMIT Reality Check on Atopic Dermatitis (2Q2023)
A review of market access for atopic dermatitis treatments shows that under the pharmacy benefit, about 43% of the lives under commercial formularies are covered with utilization management restrictions. Around 25% of the lives under health exchange formularies are not covered for at least one of the drugs.
Commercial Insurance Restrictions Complicate Biosimilar Adoption
Since the FDA’s approval of the first biosimilar in 2015, the agency has approved almost 40 more agents. However, their adoption in the U.S. market has been slow. A recent study, published in the journal BioDrugs, found that biosimilars were covered more restrictively than their reference biologics in 19.4% of coverage decisions made by select commercial health plans.
The study examined 1,181 coverage decisions made by 17 commercial health plans as of August 2021 from the Tufts Medical Center Specialty Drug Evidence and Coverage database, which included 19 commercially available biosimilars for seven biologic reference products used in treating 28 conditions.
As Weight Loss Drugs’ Star Rises, Plan Sponsors, Researchers Worry About Costs
In recent months, the interest in prescription weight loss medications has grown exponentially as celebrities tout the drugs and clinical trial results show their safety and effectiveness. However, while tens of millions of people could benefit from the medications, health policy experts tell AIS Health that payers are taking a cautious approach and are concerned at the financial impact if the FDA approves more drugs for that indication, as is expected.
A recent survey from the International Foundation of Employee Benefit Plans found that 22.1% of employers last year offered prescription drug coverage for weight loss, including 21.3% of corporations, 22% of public employers and 27% of multiemployer plans. Of the 470 companies that responded to the survey, 25% said obesity is one of the top three health conditions that has the largest impact on overall health costs.
MMIT Reality Check on Narcolepsy (2Q2023)
A review of market access for treatments for adults with narcolepsy shows that under the pharmacy benefit, about 55% of the lives under commercial formularies are covered with utilization management restrictions. Around 11% of the lives under Medicare formularies are not covered for at least one of the drugs.
MMIT Reality Check on Hemophilia B (Factor IX) (2Q2023)
A review of market access for hemophilia B (factor IX) treatments shows that under the pharmacy benefit, about 28% of the lives under commercial formularies are covered with utilization management restrictions. Around 21% of the lives under health exchange formularies are not covered for at least one of the drugs.
GSK’s RSV Vaccine Prospects in Youngest Pediatric Patients Looks Unlikely, per FDA Label
GlaxoSmithKline Pharmaceuticals Ltd. won the first US approval for a respiratory syncytial virus vaccine on May 3 in older adults but looks like it may not be able to claim the same crown in the other key population impacted by the virus — infants and young children.
The Food and Drug Administration approval letter for GSK’s Arexvy says the agency is waiving the pediatric study requirement for children ages 0 to 2 “because there is evidence strongly suggesting that the biological product would be unsafe in this pediatric group.”
The label for Arexvy, which is indicated for adults 60 and older, says “evidence from an animal model strongly suggests that Arexvy would be unsafe in individuals younger than 2 years of age because of increased risk of enhanced respiratory disease.”
MMIT Reality Check on Anemia Due to Chronic Kidney Disease (2Q2023)
A review of market access for treatments for people with anemia due to chronic kidney disease shows that under the pharmacy benefit, about 20% of the lives under commercial formularies are covered with utilization management restrictions. Around 40% of the lives under health exchange formularies are not covered for at least one of the drugs.